A biotechnology company working inside Roseman Bioventures is gaining attention for technology that could one day change the treatment of patients with severe burns and chronic wounds.

Regenicin, Inc., a resident company at Roseman Bioventures on Roseman University of Health Sciences’ Summerlin campus, was recently featured by the Las Vegas Review-Journal’s Vegas Business for its work developing laboratory-grown skin using a patient’s own cells.

The feature offers a look inside Regenicin’s Las Vegas operations and the science behind the company’s efforts to advance regenerative cell therapies designed to repair and restore damaged tissue.

Growing Skin from a Patient’s Own Cells

Regenicin specializes in regenerative cell therapies and is advancing cultured skin technology that begins with a small sample of a patient’s healthy skin.

The patient’s cells can then be expanded in a laboratory to create living, tissue-engineered skin. Regenicin says its technology is being developed to create full-thickness skin containing both epidermal and dermal layers. A relatively small section of harvested skin can potentially be expanded to cover an area many times larger, an important consideration when treating patients who have suffered extensive burns.

Because the resulting tissue is created using the patient’s own cells, the approach is intended to produce permanent skin tissue without the immune rejection concerns associated with skin obtained from other sources.

The company is advancing its cultured skin technology for the treatment of severe burns and chronic wounds as it works toward future regulatory and clinical milestones.

Innovation Happening in Las Vegas

Regenicin’s work also demonstrates the increasingly sophisticated biotechnology research and development taking place in Southern Nevada.

As a resident company at Roseman Bioventures, Regenicin is part of a growing community of biotechnology, medical technology and medical device companies working alongside researchers, students, entrepreneurs and industry partners at Roseman University’s Summerlin campus.

Launched in 2026, Roseman Bioventures is a 120,000-square-foot life sciences incubator created to help companies translate promising scientific discoveries into commercially viable technologies and therapies. Companies have access to laboratory and office space, research infrastructure, support services, mentorship and connections to industry and investment partners.

The goal extends beyond providing laboratory space. Roseman Bioventures is building an environment where companies can grow while simultaneously helping develop the scientific workforce Southern Nevada needs to support an expanding life sciences sector.

Creating Opportunities for Roseman Students

That connection between education and industry is already taking shape inside Regenicin’s laboratory.

A Roseman University graduate student is part of the Regenicin team, gaining hands-on experience working alongside scientists advancing the company’s regenerative medicine technology.

For Roseman Bioventures, opportunities like this represent an important part of building a sustainable life sciences ecosystem. Bringing biotechnology companies to Southern Nevada creates opportunities not only for scientific discovery and economic development, but also for students to gain real-world experience and develop the skills needed for careers in biotechnology and pharmaceutical sciences.

Roseman University’s College of Graduate Studies offers Master of Science programs in Biomedical Sciences and Pharmaceutical Sciences designed in part to prepare students for careers within growing bioscience industries. Partnerships with biotechnology and other industry organizations provide opportunities for internships, mentoring and professional networking.

When emerging companies, university researchers and students work within the same ecosystem, education and innovation can reinforce one another.

Building Southern Nevada’s Life Sciences Ecosystem

Regenicin is one example of the companies helping demonstrate what is possible as Southern Nevada works to establish itself as a destination for biotechnology and life sciences.

For Roseman Bioventures, seeing a resident company receive recognition for potentially impactful science is also a reflection of the broader vision behind the incubator: provide innovators with the infrastructure and environment they need to advance their work while creating new connections among industry, academia, investors and the community.

Most importantly, the work happening in these laboratories is ultimately about patients.

Technologies being developed today have the potential to become tomorrow’s treatments, and Regenicin’s efforts to engineer living skin for people suffering from catastrophic burns illustrate the kind of real-world healthcare challenges that biotechnology can help address.

Read the full Las Vegas Review-Journal/Vegas Business feature:
Las Vegas company grows patients’ skin in lab to treat severe burns